What leads people with dengue, chikungunya, or other arbovirus infections to need hospital care in the Indian Ocean
Official title: Factors Associated With Hospitalization and Severity of Arbovirosis in the Indian Ocean
Run by Centre Hospitalier Universitaire de la Réunion · NCT07119086 · Data updated 2026-11-12
This project will try to find which clinical, demographic, or laboratory factors make people with dengue, chikungunya, Zika, or other arbovirus infections more likely to be hospitalized or to develop severe disease in the Indian Ocean region.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de la Réunion Academic / other |
| Locations | 1 site (Saint-Pierre) |
| Status | Recruiting |
| Started | June 2, 2025 |
| Main results expected | May 5, 2037 |
| Study ends | May 5, 2037 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT07119086 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People of any age (newborns >2.5 kg, children, adults) seen in participating emergency rooms, inpatient wards, day hospitals, or outpatient clinics with suspected, probable, or confirmed arbovirosis, including newborns of viremic mothers.
✕Probably not a fit
People without arbovirus infection, those who do not present to participating hospitals, or individuals whose illness is unrelated to arboviruses may not receive direct benefit from this work.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Patients of all ages presenting to participating hospital departments in Réunion with suspected, probable, or confirmed arbovirosis will be enrolled. The team will collect biological samples and administer standardized questionnaires to gather clinical history, symptoms, exposures, and demographic information. Laboratory testing will determine virus type/serotype and relevant biomarkers while clinical records will capture hospitalization and severity outcomes. Statistical analyses will look for associations between host factors, virus characteristics, and risk of hospitalization or severe disease.
Why it matters
Potential benefit: If successful, the findings could help clinicians identify patients at higher risk so they can be monitored or treated sooner to prevent severe outcomes.
How similar studies have gone: Similar observational studies of dengue and chikungunya in other settings have identified clinical and demographic risk factors, so this approach builds on existing evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
1st case : Inclusion Criteria: * Adult, child or newborn \> 2.5kg on day of inclusion. * Use of one of the hospital departments participating in the research, in an emergency room, full hospitalization, day hospitalization or outpatient clinic. * Suspected, probable or biologically confirmed arbovirosis: A suspected case of arbovirosis is defined as : * asymptomatic contact case of a patient with probable or confirmed arbovirosis * symptomatic or non-symptomatic newborns of mothers who were viremic for arbovirosis during pregnancy, or who had probable or confirmed arbovirosis during pregnancy. * In a patient with a history of a stay in an arbovirus circulation zone in the 2 weeks prior to consultation (for imported cases only). * In a patient with compatible clinical symptoms during the epidemic period A probable case of arbovirosis is defined by : * the association of at least 2 objectified or reported signs or biology suggestive of arbovirosis: fever (reported by the patient or family, or documented), headache, rash, myalgias, arthralgias, abdominal pain, bleeding, thrombocytopenia, or * for children under 6: by the reporting (by the family or documented) of a fever on the day of inclusion or in the preceding 7 days, possibly accompanied by pain. A biologically confirmed case of arbovirosis is defined by : \- A positive plasma RT-PCR or urine RT-PCR (Zika virus) Case 2 : - Retrospectively, patients with sufficiently documented definite, probable or suspected arbovirosis, who give oral consent for their data to be collected retrospectively and/or to continue the study follow-up. Exclusion Criteria: 1\. Patient ou titulaire de l'autorité parentale non affiliés ou non bénéficiaires d'un régime de sécurité sociale.
Where it's running
-
Prct
Saint-Pierre, France Recruiting
Study contacts
- Study coordinator: CHU La Réunion DRCI
- Email: melanie.begorre@chu-reunion.fr
- Phone: 0262717885
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Characterizing T-cell responses to arbovirus infections using ELISpot tests
This project will test whether ELISpot blood assays can detect T-cell immune responses in adults with suspected arbovirus infections.
-
Tracking mosquito-borne and other emerging virus infections in Fiji
This project will follow people aged 6 and older who live in Fiji's Central Division to see how often mosquito-borne and respiratory viruses infect them over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.